breyanzi
bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - antineoplastiske midler - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.
klexane 4000 iu
sanofi-aventis norge as (1) - enoksaparinnatrium - injeksjonsvæske, oppløsning - 4000 iu
klexane 2000 iu
sanofi-aventis norge (3) - enoksaparinnatrium - injeksjonsvæske, oppløsning - 2000 iu
klexane 6000 iu
sanofi-aventis norge as (1) - enoksaparinnatrium - injeksjonsvæske, oppløsning - 6000 iu
klexane 8000 iu
sanofi-aventis norge as (1) - enoksaparinnatrium - injeksjonsvæske, oppløsning - 8000 iu
klexane 10000 iu
sanofi-aventis norge as (1) - enoksaparinnatrium - injeksjonsvæske, oppløsning - 10000 iu
klexane 12000 iu
sanofi-aventis norge (3) - enoksaparinnatrium - injeksjonsvæske, oppløsning - 12000 iu
klexane 15000 iu
sanofi-aventis norge as (1) - enoksaparinnatrium - injeksjonsvæske, oppløsning - 15000 iu
klexane 30000 iu/3 ml
sanofi-aventis norge (3) - enoksaparinnatrium - injeksjonsvæske, oppløsning - 30000 iu/3 ml
losartan/hydrochlorothiazide krka 100 mg / 25 mg
krka sverige ab - losartankalium / hydroklortiazid - tablett, filmdrasjert - 100 mg / 25 mg